These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10719423)

  • 21. Serum soluble Fas level for detection and staging of prostate cancer.
    Furuya Y; Fuse H; Masai M
    Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 24. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
    Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
    J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between age and Chromogranin A determination in prostate diseases.
    Mearini L; Zucchi A; Scarponi E; Nunzi E; Aglietti MC; Bini V; Porena M
    Cancer Biomark; 2011-2012; 10(3-4):117-23. PubMed ID: 22674297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer].
    Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu
    Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prognostic factors in prostate cancer. Review of the literature and future perspectives].
    Cussenot O; Ravery V; Desgrandchamps F; Cochand-Priollet B; Teillac P; Le Duc A
    Prog Urol; 1994 Feb; 4(1):17-30. PubMed ID: 7514473
    [No Abstract]   [Full Text] [Related]  

  • 31. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
    van der Kwast TH
    Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
    [No Abstract]   [Full Text] [Related]  

  • 33. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
    Isshiki S; Akakura K; Komiya A; Suzuki H; Kamiya N; Ito H
    J Urol; 2002 Feb; 167(2 Pt 1):512-5. PubMed ID: 11792908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate gland: anatomy, hyperplasia, cytologic atypia, adenocarcinoma, and tumor markers.
    Gray JM
    Prog Clin Biol Res; 1987; 237():15-29. PubMed ID: 3317426
    [No Abstract]   [Full Text] [Related]  

  • 35. Skin metastasis of prostate adenocarcinoma to glans penis showing no correlation with serum prostate-specific antigen level.
    Kobashi-Katoh R; Tanioka M; Takahashi K; Miyachi Y
    J Dermatol; 2009 Feb; 36(2):106-8. PubMed ID: 19284456
    [No Abstract]   [Full Text] [Related]  

  • 36. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for prostate cancer in 2007: the PSA era and its challenges are not over.
    Shariat SF; Karakiewicz PI
    Eur Urol; 2008 Mar; 53(3):457-60. PubMed ID: 18079050
    [No Abstract]   [Full Text] [Related]  

  • 40. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
    Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
    Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.